These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
606 related articles for article (PubMed ID: 30795755)
41. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis. Colanta A; Lin O; Tafe L; Ghossein R; Nafa K; Mitchell T; Ladanyi M; Arcila M Acta Cytol; 2011; 55(6):563-9. PubMed ID: 22156467 [TBL] [Abstract][Full Text] [Related]
42. Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207 [TBL] [Abstract][Full Text] [Related]
43. Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Management--A Case Report. Shrestha RT; Karunamurthy A; Amin K; Nikiforov YE; Caramori ML Thyroid; 2015 Dec; 25(12):1375-8. PubMed ID: 26355276 [TBL] [Abstract][Full Text] [Related]
44. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120 [TBL] [Abstract][Full Text] [Related]
45. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181 [TBL] [Abstract][Full Text] [Related]
46. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples. Dyhdalo K; Macnamara S; Brainard J; Underwood D; Tubbs R; Yang B Cancer Cytopathol; 2014 Feb; 122(2):114-22. PubMed ID: 24150898 [TBL] [Abstract][Full Text] [Related]
47. Isolated Langerhans cell histiocytosis of the thyroid in a female infant. Hung CS; Yeh YC; Chen JC; Jung SM; Hung IJ; Lo FS Eur J Pediatr; 2007 Nov; 166(11):1151-3. PubMed ID: 17372761 [TBL] [Abstract][Full Text] [Related]
48. BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer. Liu Z; Lv T; Xie C; Di Z Am J Med Sci; 2018 Aug; 356(2):130-134. PubMed ID: 30219154 [TBL] [Abstract][Full Text] [Related]
49. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis. Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356 [TBL] [Abstract][Full Text] [Related]
50. Predictive Value of BRAF Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513 [TBL] [Abstract][Full Text] [Related]
51. Langerhans cell histiocytosis of the lung and thyroid, co-existing with papillary thyroid cancer. Jamaati HR; Shadmehr MB; Saidi B; Khosravi A; Arab M; Mohammadi F Endocr Pathol; 2009; 20(2):133-6. PubMed ID: 19337865 [TBL] [Abstract][Full Text] [Related]
52. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709 [TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144 [TBL] [Abstract][Full Text] [Related]
54. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma]. Wang J; Liu LT; Cui D; He L; Liu DG Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264 [No Abstract] [Full Text] [Related]
55. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. Tang KT; Lee CH J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995 [TBL] [Abstract][Full Text] [Related]
56. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Strupas K Langenbecks Arch Surg; 2017 Mar; 402(2):227-234. PubMed ID: 28160058 [TBL] [Abstract][Full Text] [Related]